Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE

Monte Rosa Therapeutics

Monte Rosa Therapeutics patent portfolio — 72 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Employees
213
Programs
7
Drugs
14
Patents
72
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Monte Rosa Therapeutics patents

72 pharmaceutical patents indexed for Monte Rosa Therapeutics. 5 expire within 24 months.

Monte Rosa Therapeutics has 72 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 5 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

72 patents

Patent portfolio

Page 2 of 2

  1. US 8071380

    Skeletal muscle periangioblasts and cardiac mesangioblasts, method for isolation and uses thereof

    Expires Mon Dec 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7833789

    Monocyte cell

    Expires Mon Nov 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7795386

    Peptides comprising an isoDGR motif

    Expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7763292

    Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts

    Expires Mon Jul 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7737256

    Antibody against uPA/uPAR

    Expires Mon Jun 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7622105

    Modified cytokines for use in cancer therapy

    Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7622556

    Modified cytokines for use in cancer therapy

    Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7556804

    Anti-HGF-R antibodies and their use

    Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7479483

    Tumor-targeted drug delivery systems and uses thereof

    Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7476721

    Modified cytokines for use in cancer therapy

    Expires Mon Jan 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7309694

    Modified cytokines for use in cancer therapy

    Expires Mon Dec 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7268122

    Use of oversulfated polysaccharides as inhibitors of HIV

    Expires Mon Sep 06 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7164000

    RANTES mutants and therapeutic applications thereof

    Expires Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7150869

    Modified cytokines for use in cancer therapy

    Expires Mon Dec 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7109303

    Modified cytokines for use in cancer therapy

    Expires Mon Sep 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 6841547

    Method for decreasing low density lipoprotein

    Expires Mon Jan 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  17. US 6709649

    RANTES derived peptides with anti-HIV activity

    Expires Mon Mar 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  18. US 6608177

    Rantes mutants and therapeutic applications thereof

    Expires Mon Aug 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  19. US 6462170

    UPAR mimicking peptide

    Expires Mon Oct 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  20. US 6429009

    Composition and method of imparting resistivity to HIV superinfection to cells

    Expires Mon Aug 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  21. US 6194460

    Composition for treating cough induced by angiotensin converting enzyme inhibitors

    Expires Mon Feb 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  22. US 6165738

    Expression in yeast of antigenically active, recombinant hybrid glutamic acid decarboxylase

    Expires Mon Dec 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  23. US 6072072

    Compounds for preparing modified hemoglobin

    Expires Mon Jun 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  24. US 6025399

    Method of producing neuromuscular block by the use of tetra-propyl or tetrabutylammonium compounds

    Expires Mon Feb 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Monte Rosa Therapeutics have?

72 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Monte Rosa Therapeutics patents expire?

5 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.